Integrated management of acute pulmonary embolism and the post-pulmonary embolism syndrome: risk stratification, modern therapies, and long-term follow-up
4 affiliations
- 1Department VI, Cardiology, Faculty of Medicine, “Victor Babeș” University of Medicine and Pharmacy Timișoara
- 2Department of Internal Medicine I, Faculty of Medicine, “Victor Babeș” University of Medicine and Pharmacy Timișoara
- 3Department of Infectious Diseases, Municipal Emergency Clinical Hospital Timișoara
- 4Doctoral School, “Victor Babeș” University of Medicine and Pharmacy Timișoara
Abstract
Pulmonary embolism (PE) is increasingly recognized as an episode of care that extends well beyond hospital discharge. Current guidance is distributed across several documents: the 2019 European Society of Cardiology (ESC) guidelines; the 2026 American Heart Association/American College of Cardiology (AHA/ACC) multisociety guideline, which replaced the massive/submassive terminology with clinical categories A–E; and separate position papers on catheter-directed intervention (CDI) and on follow-up. This narrative review (i) provides a side-by-side comparison of the ESC and AHA/ACC risk frameworks and their therapeutic implications; (ii) updates the evidence on reperfusion, including the recent randomized trials HI-PEITHO, PEERLESS and STORM-PE; and (iii) focuses on transitions of care and long-term follow-up, which guidelines address less comprehensively. Anticoagulation, preferably with a direct oral anticoagulant, remains the treatment for most patients. Systemic thrombolysis is reserved for high-risk (ESC) or category E (AHA/ACC) PE, because in intermediate-risk disease it halves hemodynamic decompensation at the cost of a several-fold increase in major and intracranial bleeding, without long-term functional benefit. In HI-PEITHO, ultrasound-facilitated catheter-directed thrombolysis reduced a 7-day composite outcome driven by cardiorespiratory decompensation (4.0% vs. 10.3%) in intermediate-high-risk patients with additional markers of physiological stress, without intracranial hemorrhage; a survival benefit of CDI has not been demonstrated. At discharge, a minimum bundle should specify the drug, dose, anticipated duration, provoking context, bleeding mitigation and follow-up ownership, followed by early contact within one week and a structured review at approximately three months. Up to half of survivors report persistent dyspnea or exercise limitation, whereas chronic thromboembolic pulmonary hypertension (CTEPH) develops in approximately 2%–3%. Persistent symptoms should prompt phenotype-directed evaluation with echocardiography, ventilation/perfusion scintigraphy, cardiopulmonary exercise testing and, when indicated, right-heart catheterization interpreted with the 2022 hemodynamic definitions, followed by early referral to an expert center where pulmonary endarterectomy, balloon pulmonary angioplasty and medical therapy can be combined. We state the type of evidence underpinning each key recommendation, propose a discharge bundle, a structured follow-up algorithm and episode-wide quality indicators, and identify the evidence gaps that should guide future trials.
Related
- PO001 | EMERGENCY DEPARTMENT MANAGEMENT OF PULMONARY EMBOLISM IN CANCER PATIENTS: PROGNOSTIC STRATIFICATION AND OUTCOMES
- Two Faces of the Same Thrombus: Molecular Phenotypes of Thromboinflammation in Acute Pulmonary Embolism and the Path to Phenotype-Guided Risk Stratification
- CO001 | DERIVATION AND VALIDATION OF THE BLEEPE SCORE FOR RISK STRATIFICATION OF MAJOR BLEEDING IN PATIENTS WITH ACUTE PULMONARY EMBOLISM
- Beyond Vasodilation in Pulmonary Arterial Hypertension: Integrating Remodeling-Directed Therapies into Risk-Guided Management
- Clinical research advances in pulmonary infections in 2025: a narrative review of multipathogen assessment, precision diagnosis, and integrated management
BibTeX
@article{craciun2026integrated,
title = {{Integrated management of acute pulmonary embolism and the post-pulmonary embolism syndrome: risk stratification, modern therapies, and long-term follow-up}},
author = {Maria-Laura Craciun and Cristiana Adina Avram and Ana-Maria Pah and Simina Crisan and Diana-Maria Mateescu and Ioana Cotet and Cristina Vacarescu and Oana Patru and Maria Rada},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.3389/fcvm.2026.2002611},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.2002611/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Integrated management of acute pulmonary embolism and the post-pulmonary embolism syndrome: risk stratification, modern therapies, and long-term follow-up
AU - Maria-Laura Craciun
AU - Cristiana Adina Avram
AU - Ana-Maria Pah
AU - Simina Crisan
AU - Diana-Maria Mateescu
AU - Ioana Cotet
AU - Cristina Vacarescu
AU - Oana Patru
AU - Maria Rada
PY - 2026
DA - 2026/10/21
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.2002611
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.2002611/full
AB - Pulmonary embolism (PE) is increasingly recognized as an episode of care that extends well beyond hospital discharge. Current guidance is distributed across several documents: the 2019 European Society of Cardiology (ESC) guidelines; the 2026 American Heart Association/American College of Cardiology (AHA/ACC) multisociety guideline, which replaced the massive/submassive terminology with clinical categories A–E; and separate position papers on catheter-directed intervention (CDI) and on follow-up. This narrative review (i) provides a side-by-side comparison of the ESC and AHA/ACC risk frameworks and their therapeutic implications; (ii) updates the evidence on reperfusion, including the recent randomized trials HI-PEITHO, PEERLESS and STORM-PE; and (iii) focuses on transitions of care and long-term follow-up, which guidelines address less comprehensively. Anticoagulation, preferably with a direct oral anticoagulant, remains the treatment for most patients. Systemic thrombolysis is reserved for high-risk (ESC) or category E (AHA/ACC) PE, because in intermediate-risk disease it halves hemodynamic decompensation at the cost of a several-fold increase in major and intracranial bleeding, without long-term functional benefit. In HI-PEITHO, ultrasound-facilitated catheter-directed thrombolysis reduced a 7-day composite outcome driven by cardiorespiratory decompensation (4.0% vs. 10.3%) in intermediate-high-risk patients with additional markers of physiological stress, without intracranial hemorrhage; a survival benefit of CDI has not been demonstrated. At discharge, a minimum bundle should specify the drug, dose, anticipated duration, provoking context, bleeding mitigation and follow-up ownership, followed by early contact within one week and a structured review at approximately three months. Up to half of survivors report persistent dyspnea or exercise limitation, whereas chronic thromboembolic pulmonary hypertension (CTEPH) develops in approximately 2%–3%. Persistent symptoms should prompt phenotype-directed evaluation with echocardiography, ventilation/perfusion scintigraphy, cardiopulmonary exercise testing and, when indicated, right-heart catheterization interpreted with the 2022 hemodynamic definitions, followed by early referral to an expert center where pulmonary endarterectomy, balloon pulmonary angioplasty and medical therapy can be combined. We state the type of evidence underpinning each key recommendation, propose a discharge bundle, a structured follow-up algorithm and episode-wide quality indicators, and identify the evidence gaps that should guide future trials.
SN - 2297-055X
ER -